This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: F21 (Schizotypal disorder) | Special Copayment Reduction: V161 (severe intractable disease, 5 years) |
| B. Synonyms | latent schizophrenic reaction, borderline schizophrenia, latent schizophrenia, prepsychotic schizophrenia, prodromal schizophrenia, pseudoneurotic schizophrenia, pseudopsychopathic schizophrenia, schizotypal personality disorder |
| C. Adult onset | High likelihood of first onset in adulthood — symptoms often become fully manifest in early adulthood (ages 18–25), and social isolation, odd thinking, and perceptual distortions commonly reach clinical level for the first time as the person becomes an adult. |
| 1. History | Listed as an independent diagnostic category in DSM-III in 1980; Rado (1953) proposed the concept of schizotypy; Meehl (1962) established the diathesis-stress model; classified as a psychotic spectrum disorder in ICD-10 (1992). |
| 2. Causes | Combined action of genetic vulnerability (schizophrenia spectrum genes), abnormal dopamine and glutamate neurotransmission, early developmental impairment, and environmental stress (urban residence, immigration, traumatic experiences). |
| 3. Genetics | Increased incidence in first-degree relatives of patients with schizophrenia; shared schizophrenia-related genes such as DISC1, NRG1, and DTNBP1; heritability estimated at about 50–70% in twin studies. |
| 4. General epidemiology | Prevalence about 3% of the general population; slightly higher in men; occurs in about 10–15% of first-degree relatives of patients with schizophrenia; prevalence including schizophrenia spectrum disorders estimated at about 0.4–0.6% in the Korean mental disorders survey. |
| 5. Pathophysiology | Abnormal prefrontal-limbic connectivity, dopamine D2 receptor hypersensitivity, reduced NMDA receptor function, limbic overactivation, and neurocognitive deficits (attention, working memory) are the core pathology. |
| 6. Symptoms | Odd thinking and speech, magical thinking, abnormal perceptual experiences (illusions), excessive social anxiety, social isolation, paranoid ideation, flat or inappropriate affect. |
| 7. Signs | Odd appearance or behavior, derailed train of thought, shallow affect, difficulty with social communication, impaired attention, processing speed, and executive function on cognitive testing. |
| 8. Screening | Standardized self-report scales such as the Schizotypal Personality Questionnaire (SPQ), Chapman Scales, and Wisconsin Schizotypy Scales; clinical interview of persons with a family history of schizophrenia. |
| 9. Diagnosis | ICD-10 F21 diagnostic criteria: at least 4 of 9 characteristic symptoms persisting for at least 2 years; differentiation from schizophrenia, personality disorders, anxiety disorders, etc. is essential; cognitive deficits assessed by neuropsychological testing. |
| 10. Treatment | Low-dose antipsychotics (risperidone, olanzapine), cognitive behavioral therapy (CBT), social skills training, supportive psychotherapy, and, when needed, an SSRI added for accompanying anxiety or depressive symptoms. |
| 11. Prognosis | About 10–20% progress to schizophrenia (based on long-term follow-up studies); most have a chronic course but maintain function without severe psychotic episodes; early intervention and social support are important for improving prognosis. |
| 12. Prevention | Early detection of persons at high risk for schizophrenia, stress management, prevention of substance abuse, strengthening of social support networks; preventive counseling and regular monitoring for families of patients with schizophrenia. |
| 13. References | Raine A. Schizotypal personality: Neurodevelopmental and psychosocial trajectories. Annu Rev Clin Psychol. 2006 … and 9 other papers |
The conceptual history of schizotypal disorder developed as understanding of the schizophrenia spectrum deepened. In the early 20th century, Eugen Bleuler described borderline cases of schizophrenia with the concept of 'latent schizophrenia', which was the first recording in the clinical literature that schizophrenia-like symptoms can appear without a full psychotic episode. In 1921, Ernst Kretschmer, studying the relationship between body type and personality, described that people with a 'schizoid' temperament show odd thinking and social isolation even without full schizophrenia.
The modern concept of schizotypy was first formulated in 1953 by the American psychiatrist Sandor Rado. Rado coined the new term 'schizotypy' to describe a state in which there is a genetic predisposition to schizophrenia but full onset does not occur. In 1962, Paul Meehl refined the concept further and presented the diathesis-stress model, explaining schizotypy as the phenotype that appears when a genetic neural integrative deficit called 'schizotaxia' interacts with environmental stress. Meehl's theory remains the theoretical foundation of schizotypal disorder research to this day.
An important turning point in the history of diagnostic classification was the large-scale adoption study conducted in Denmark (Kety et al.) in 1968. It showed markedly higher schizotypal traits in the biological relatives of patients with schizophrenia, systematically demonstrating for the first time that schizotypy is a spectrum condition genetically related to schizophrenia. These findings contributed decisively to the first listing of schizotypal personality disorder as an independent diagnostic category in DSM-III in 1980.
In the course of the international classification of diseases, ICD-10 (1992) placed schizotypal disorder (F21) not among the personality disorders but among the psychotic spectrum disorders, that is, in the F2 group (schizophrenia, schizotypal, and delusional disorders). This is an important difference from the DSM system (which classifies it as a personality disorder), and the ICD-10 classification reflects a position that places greater emphasis on the biological and genetic continuity of schizotypy with schizophrenia. In ICD-11, which took effect in 2022, schizotypal disorder was also kept in the group 'schizophrenia or other primary psychotic disorders' (6A23), with the diagnostic criteria somewhat refined. DSM-5 (2013) adopted a unique classification approach, keeping schizotypal personality disorder in personality disorder Cluster C while also listing it as a cross-reference under the schizophrenia spectrum disorders. In Korea it was formerly called schizoid-type personality disorder and was later standardized to the term schizotypal, and in view of its continuity with schizophrenia it is included among the conditions eligible for the severe intractable disease Special Copayment Reduction (V161).
The cause of schizotypal disorder is explained by a multifactorial model in which genetic vulnerability, neurobiological abnormalities, developmental factors, and environmental stress interact in a complex way. It is not explained by a single cause, and the so-called diathesis-stress model is the most widely accepted explanatory framework.
Genetic factors: The markedly higher incidence of schizotypal disorder in first-degree relatives of patients with schizophrenia suggests a strong genetic contribution. In twin studies, concordance in monozygotic twins is significantly higher than in dizygotic twins (about 33% versus 4%), and overall heritability is estimated at 50–70%. The genetic architecture of schizotypy overlaps considerably with that of schizophrenia, and the two disorders are thought to be related through some shared genetic variants. The high incidence of schizotypal traits in chromosome 22q11.2 deletion syndrome (velo-cardio-facial syndrome) is also evidence of genetic association.
Neurotransmitter abnormalities: There is evidence that abnormalities of the dopamine system are related to the positive symptoms of schizotypal disorder (odd thinking, magical thinking, perceptual distortions). PET studies have observed that striatal dopamine synthesis capacity in patients with schizotypy is higher than in normal controls and lower than in patients with schizophrenia, at an intermediate level. The glutamate system, in particular the hypothesis of reduced NMDA receptor function, is also a strong explanation for the negative symptoms and cognitive deficits of schizotypy. This is supported by the fact that administration of ketamine (an NMDA antagonist) induces schizotypy-like symptoms in healthy people. Altered serotonin 5-HT2A receptor activity is also presumed to be involved in perceptual distortion symptoms.
Neurodevelopmental factors: Prenatal viral infection (especially influenza), obstetric complications (hypoxia at birth), maternal stress, and nutritional deficiency (folate) can affect fetal neurodevelopment and increase later vulnerability to the onset of schizotypal symptoms. The association between infection exposure in the second trimester and later increased risk of psychotic spectrum disorders is supported by several epidemiological studies. Delayed developmental milestones in infancy and childhood, problems adjusting to school, and difficulties in peer relationships are often reported retrospectively by adults with schizotypy.
Environmental stress: Environmental factors such as urban residence, immigration experience, childhood abuse or neglect, social exclusion, and cannabis use trigger or worsen schizotypal symptoms in individuals with genetic vulnerability. The concept of social defeat explains that chronic feelings of social inferiority and exclusion induce a dopamine-hypersensitive state and increase positive symptoms. Childhood trauma (physical, sexual, and emotional abuse) shows a significant correlation with the severity of schizotypal symptoms.
The genetics of schizotypal disorder is closely related to the genetics of schizophrenia, and research exploring the genetic basis shared by the two disorders has been active. Schizotypal disorder is also regarded as a genetic spectrum endophenotype of schizophrenia, meaning an intermediate phenotype that reflects the related genetic burden without progressing to full schizophrenia.
Family and adoption studies: The classic Danish adoption studies (Kety et al., 1968, 1994) confirmed that schizotypal traits occur markedly more often in the biological relatives of index patients with schizophrenia, and that this is associated with the biological family (genetic influence) rather than the adoptive family (environmental influence). These results were the first systematic demonstration that schizotypy is a spectrum condition sharing genes with schizophrenia. About 10–15% of first-degree relatives of patients with schizophrenia meet the criteria for schizotypal disorder, which is 3–5 times the general population prevalence (about 3%).
Candidate gene studies: Several genes known to be shared with schizophrenia are also associated with schizotypal traits. The DISC1 (disrupted in schizophrenia 1) gene is involved in neurodevelopment and synaptic plasticity, and variants of this gene are associated with schizotypy trait scores. Specific haplotypes of NRG1 (neuregulin-1) are associated with cognitive function, particularly working memory and processing speed, and NRG1-related cognitive phenotypes have been reported in patients with schizotypy. DTNBP1 (dysbindin) affects prefrontal function and dopamine synaptic transmission, and association study results have been reported in both schizotypy and schizophrenia. The COMT (catechol-O-methyltransferase) Val158Met polymorphism affects prefrontal dopamine metabolism and is associated with cognitive and social function, and the influence of this variant on the schizotypal phenotype has also been studied.
Genome-wide association studies (GWAS): Common variant (SNP) loci identified in large schizophrenia GWAS (more than 108 genomic loci identified, Schizophrenia Working Group 2014) show multifaceted associations with schizotypal traits. In studies using polygenic risk scores (PRS), higher schizophrenia PRS tends to accompany higher schizotypal symptom scores, supporting the genetic continuity of the two disorders. Chromosome 22q11.2 deletion (DiGeorge syndrome) is known to lead to schizotypal traits or schizophrenia in about 30% of adults, showing that specific copy number variants (CNV) are strongly associated with the schizotypy spectrum.
Epigenetics: Epigenetic research findings are accumulating that environmental stress, particularly childhood trauma, alters the methylation patterns of neurodevelopment-related genes (BDNF, FKBP5, NR3C1, etc.) and contributes to the onset of schizotypal symptoms. Because such epigenetic changes can be transmitted across generations, a hypothesis has also been raised that stress exposure in the parental generation may affect schizotypal vulnerability in offspring.
Schizotypal disorder shows a relatively low prevalence in the general population, but it is a mental health problem consistently reported in several epidemiological studies. Worldwide, about 3% of the general population is estimated to meet clinical diagnostic criteria for schizotypal traits, which is higher than for schizophrenia (about 1%). However, prevalence estimates may vary somewhat depending on the diagnostic system (ICD-10 versus DSM-5).
Sex and age distribution: Schizotypal disorder tends to show a slightly higher prevalence in men. The male-to-female ratio is reported to be about 1.5:1. Initial symptoms mainly emerge in late adolescence or early adulthood (ages 18–25), similar to the age of onset of schizophrenia. However, schizotypy has a more gradual symptom onset than schizophrenia and often follows a chronic course without a full psychotic episode. Prodromal symptoms such as social awkwardness, difficulty in peer relationships, and learning problems may appear in childhood, but formal diagnosis is mostly made in early adulthood.
Incidence within families of patients with schizophrenia: In first-degree relatives of patients with schizophrenia, the risk of schizotypal disorder is 3–5 times higher than in the general population. This suggests that schizotypal disorder is part of the genetic phenotype of schizophrenia, and provides the clinical basis for regular monitoring of families at high risk for schizophrenia. When a family member has schizophrenia, systematic assessment of schizotypal traits in the remaining family members is recommended.
Epidemiology in Korea: According to data from the Korean Epidemiologic Catchment Area Study of Psychiatric Disorders (KCPES), the lifetime prevalence of schizophrenia and related psychotic disorders is about 0.5%, and the prevalence of all schizophrenia spectrum disorders including schizotypal disorder is presumed to be higher. In Korea, epidemiological data reporting schizotypal disorder alone are limited, and it is often counted as part of schizophrenia spectrum disorders. In analyses based on Health Insurance Review & Assessment Service (HIRA) claims data, the number of patients treated under the F21 code is reported to be in the range of several thousand per year.
Comorbidity: Schizotypal disorder shows high comorbidity rates with major depressive disorder (comorbid in about 30–50%), social anxiety disorder, obsessive-compulsive disorder, and attention-deficit/hyperactivity disorder (ADHD). Comorbidity with substance use disorders (especially cannabis and alcohol) is also clinically important, as substance use worsens schizotypal symptoms and raises the risk of transition to schizophrenia. The presence of comorbid diagnoses increases treatment complexity and also negatively affects prognosis.
The neurobiological pathophysiology of schizotypal disorder overlaps considerably with that of schizophrenia but is characterized by differences in severity and extent. Overall, functional and structural abnormalities of the prefrontal-limbic circuit are accepted as the core pathology.
Dopamine system abnormalities: PET imaging studies have confirmed increased striatal dopamine synthesis capacity in patients with schizotypal disorder. It is at an intermediate level between schizophrenia (greater dopamine excess) and normal controls, which explains why the degree of positive symptoms (odd thinking, paranoid ideation) is milder than in schizophrenia. Reduced dopamine D1 receptor activity in the prefrontal cortex is presumed to cause working memory and executive function deficits.
Reduced glutamate-NMDA receptor function: Reduced NMDA receptor function causes decreased GABAergic interneuron function, which leads to excessive cortical excitability and abnormal sensory information processing. This mechanism is useful for explaining the perceptual distortions (illusions, abnormal perceptual experiences) and information-processing bias symptoms of schizotypy. Abnormalities of glutamatergic markers (glutamine/glutamate ratio) in patients with schizotypy have been reported in magnetic resonance spectroscopy (MRS) studies.
Structural brain abnormalities: In MRI studies, patients with schizotypy show reduced gray matter volume in the prefrontal cortex (dorsolateral prefrontal cortex, DLPFC) and temporal lobe (superior temporal gyrus, STG) compared with normal controls. Reduced hippocampal volume has also been reported, which is associated with abnormalities in contextual memory processing and similarity detection (excessive pattern recognition, the basis of magical thinking). The degree of structural abnormality is intermediate compared with patients with schizophrenia, reflecting the spectrum continuity between schizotypy and schizophrenia.
Functional neuroimaging findings: Using fMRI during cognitive task performance, abnormal DLPFC activation patterns (underactivation or overactivation) and abnormal connectivity of the frontoparietal network have been reported. Abnormal activation of the default mode network (DMN) is associated with excessive inner monologue and increased self-referential thinking, explaining the magical thinking and self-referential ideation of schizotypy. A deficit in P50 auditory sensory gating suppression is an electrophysiological abnormality observed in both schizophrenia and schizotypy, reflecting a deficit in sensory information filtering.
Neurocognitive deficits: Patients with schizotypy show significant impairment compared with normal controls in several neurocognitive domains, including attention, processing speed, working memory, verbal learning, and executive function, but less severely than patients with schizophrenia. These neurocognitive deficits are not a direct result of symptoms but reflect neurobiological substrate abnormalities, and are closely related to functional prognosis.
The symptoms of schizotypal disorder are classified in ICD-10 into 9 groups of characteristic symptoms, and diagnosis is possible when 4 or more of these persist for at least 2 years. Symptoms can be broadly divided into positive-like and negative-like symptoms, but full psychotic episodes (hallucinations, delusions) do not occur or are experienced only very transiently.
Odd thinking and speech: Thinking is peculiar and illogical, and speech is somewhat circumstantial or vague. Thoughts tend to be loosely connected or to flow in directions unrelated to the surrounding situation. Metaphorical or symbolic language may be overused, and neologisms or expressions difficult for ordinary people to understand may be used. However, complete thought disorganization or incomprehensible 'word salad', as in schizophrenia, does not occur.
Magical thinking and odd beliefs: Strong belief in supernatural phenomena (telepathy, premonitory dreams, magic, fortune-telling, etc.), the belief that one has special powers or abilities, and thought patterns that ordinary people regard as superstitious are prominent. These beliefs markedly exceed what is culturally accepted, and the patient also tends to rationalize them. Magical thinking is also associated with a cognitive bias of being able to know other people's thoughts or feelings directly.
Abnormal perceptual experiences: Illusions that do not amount to full hallucinations, bodily abnormality sensations (somatic illusions), depersonalization or derealization experiences, and hypersensitive reactions to sensory stimuli occur. These include a sense of presence as if someone were beside the patient (sensed presence experiences), the feeling of one's name being called, and the experience of finding meaningful patterns in everyday objects (overwhelming feelings, premonitions).
Paranoid ideation and suspiciousness: There are ideas of reference, in which the patient feels that other people's actions or events are specially related to him or her, excessive suspicion of others, and a belief that there are hidden intentions or meanings in the surrounding environment. Such paranoid ideation does not reach the level of delusional conviction, and the patient can, to some extent, entertain doubt when confronted.
Social isolation and excessive anxiety: Characterized by marked difficulty forming close relationships, having no close people or not wanting any, and extreme anxiety in social situations. Unlike social anxiety disorder, this anxiety does not decrease with familiarity and often stems from paranoid fears. Emotional expression is restricted or inappropriate, and recognition of other people's emotional cues is inaccurate.
The clinical signs of schizotypal disorder are identified through psychiatric interview and physical observation, and several characteristic findings appear even without evidence of a full psychotic episode.
Oddness of appearance and behavior: Peculiar and irregular dress, unconventional behavior patterns, and socially inappropriate responses may be observed. Facial expression is restricted or emotional expression is irregular, and eye contact is often unnatural. Incongruent affect may occur, in which nonverbal communication (gestures, facial expression) does not match the verbal content.
Abnormalities of thought and speech: During the interview, circumstantial or impoverished thought content, excessive detail or figurative expression, abstract answers to concrete questions, and tangential associations are observed. There is no complete thought disorganization, but the observer may find it difficult to follow the flow of conversation. Neologisms or expressions difficult for ordinary people to understand may also be used.
Impaired social functioning: Occupational and academic functioning is impaired, which is directly related to cognitive deficits and difficulty in social interaction. The relationship network is markedly limited, and there is often almost no social network outside the family. Understanding of social norms is lacking, or there is difficulty following them.
Neuropsychological test findings: Increased false alarm rate and reduced processing speed on the Continuous Performance Test (CPT); relatively reduced Working Memory Index and Processing Speed Index on the Wechsler Adult Intelligence Scale (WAIS); executive function deficits on the Stroop test and Wisconsin Card Sorting Test (WCST); and reduced verbal memory (verbal fluency, story recall) are consistently observed in schizotypal disorder. These neurocognitive findings are useful as a diagnostic aid and for assessing functional prognosis.
Neurological soft signs: Neurological soft signs such as coordination abnormalities, mirror movements, and difficulty with sensory integration are significantly more frequent in schizotypal disorder than in normal controls. These are considered a reflection of neurodevelopmental abnormality and are used as indirect indicators of the neurological substrate.
Universal screening of the general population for schizotypal disorder is currently not standardized, but systematic screening is recommended for groups at high risk for schizophrenia (first-degree relatives of patients with schizophrenia, adolescents referred for a clinical high-risk state).
Standardized self-report scales: The Schizotypal Personality Questionnaire (SPQ) is the most widely used schizotypy screening tool; it consists of 74 items and measures three factors: cognitive-perceptual deficits, interpersonal difficulties, and odd thinking and behavior. The Chapman Scales (Perceptual Aberration, Magical Ideation, Physical Anhedonia, and Social Anhedonia scales) are useful for measuring various subsymptoms of schizotypy individually. The Wisconsin Schizotypy Scales focus on cognitive-perceptual aberrations and social anhedonia. The Oxford-Liverpool Inventory of Feelings and Experiences (O-LIFE) is used for multidimensional assessment of schizotypy.
Structured interview instruments: The Structured Interview for DSM-IV Personality Disorders (SIDP-IV or SCID-II), the schizotypal subscale of the Positive and Negative Syndrome Scale (PANSS), and the Present State Examination (PSE) are used as clinical interview tools. Structured interviews for assessing the clinical high risk (CHR) state (CAARMS, SIPS/SOPS) are useful for systematically assessing schizotypal traits in adolescents and young adults with psychosis prodromal symptoms.
Neuropsychological testing: Neuropsychological test batteries such as the Continuous Performance Test (CPT), Wechsler Adult Intelligence Scale (WAIS), California Verbal Learning Test (CVLT), and executive function tests (WCST, Stroop) are used as a complement to identify the cognitive deficit profile of schizotypal disorder and assess the risk of schizophrenia.
Screening programs for groups at high risk for schizophrenia: In Korea, early psychosis screening programs based on mental health welfare centers, such as 'Maeum-Ieum', are in operation, and a system has been established to detect and intervene early in psychosis prodromal symptoms, including schizotypal symptoms, in adolescents and young adults. Mental health screening instruments (K-CIS, K-ACES, etc.) are used for community-level screening.
Diagnosis of schizotypal disorder is based on ICD-10 F21 or the DSM-5 criteria for schizotypal personality disorder, and is made through detailed psychiatric interview, history taking, and cognitive assessment. It is important to thoroughly exclude other mental disorders and medical causes before diagnosis.
ICD-10 F21 diagnostic criteria: At least 4 of the following 9 features must be present continuously or repeatedly for at least 2 years: ① inappropriate or constricted affect; ② odd, eccentric, or peculiar behavior or appearance; ③ poor rapport with others and a tendency to social withdrawal; ④ odd beliefs or magical thinking that influences behavior; ⑤ suspiciousness or paranoid ideas, including ideas of reference; ⑥ obsessive ruminations (such as those concerning bodily abnormalities); ⑦ unusual perceptual experiences including illusions, depersonalization, derealization, and other abnormal perceptions; ⑧ vague, circumstantial, metaphorical thinking or speech; ⑨ occasional transient quasi-psychotic episodes with intense illusions, auditory hallucinations, etc., which do not persist without external stimuli.
DSM-5 criteria for schizotypal personality disorder: In DSM-5 it belongs to personality disorder Cluster B (previously classified as Cluster C) and is described in a way that acknowledges its association with the schizophrenia spectrum. It is diagnosed when a pattern of social and interpersonal deficits beginning in early adulthood appears pervasively, together with cognitive or perceptual distortions and eccentricity of behavior. At least 5 of the 9 items of Criterion A must be met.
Differential diagnosis: Schizophrenia (differentiated by whether the criteria for a full psychotic episode are met), schizoid personality disorder (emotional detachment is similar but there is no odd thinking or perceptual distortion), paranoid personality disorder (paranoid thinking is the main feature but without the other features of schizotypy), autism spectrum disorder (social communication deficits are similar but repetitive behaviors and restricted interests are characteristic), obsessive-compulsive disorder (rumination and obsessive thoughts are similar but ego-dystonic features differ), borderline personality disorder (transient stress-related dissociation and paranoid thinking are similar but intense emotional instability is characteristic), and substance use disorder (cannabis and others can induce schizotypy-like symptoms) must be thoroughly differentiated.
Ancillary tests: Neuroimaging (brain MRI) to exclude organic causes (brain lesions, encephalitis); blood tests (thyroid function, metabolic panel, autoimmune antibodies, drug screening) to exclude medical causes; neuropsychological testing to identify the cognitive profile and assess function; EEG when necessary to exclude epileptic psychosis.
Treatment of schizotypal disorder aims at symptom relief, maintenance of function, and prevention of transition to schizophrenia, and a combination of drug treatment and psychosocial treatment is recommended as the most effective approach. To date, no drug has been specifically developed and approved only for schizotypal disorder, and treatment is based on evidence extrapolated from experience in treating schizophrenia.
Drug treatment — antipsychotics: Low-dose atypical antipsychotics are reported to be effective for the positive-like symptoms of schizotypal disorder (magical thinking, paranoid ideation, perceptual abnormalities). Low-dose regimens such as risperidone 0.25–2 mg/day, olanzapine 2.5–5 mg/day, and quetiapine 25–100 mg/day are used in clinical practice. Evidence at the level of randomized controlled trials (RCT) is limited, but the effects of risperidone and olanzapine have been reported in several small RCTs and cohort studies. Effects on odd thinking, paranoid ideation, and perceptual abnormalities tend to be relatively greater than on negative-like symptoms (social isolation, flat affect).
Drug treatment — antidepressants and anxiolytics: SSRIs (selective serotonin reuptake inhibitors) are used as first choice for major depression or social anxiety disorder accompanying schizotypal disorder. Fluoxetine, escitalopram, sertraline, and others help relieve social anxiety and depressive symptoms. Benzodiazepines may be used for relief of acute anxiety but are limited to short duration and minimum dose considering the risk of abuse and possible cognitive impairment.
Cognitive behavioral therapy (CBT): Cognitive behavioral therapy targeting the magical thinking, paranoid ideation, and odd beliefs of schizotypal disorder is reported to help reduce symptoms and improve function. It includes examination of beliefs through Socratic questioning, cognitive restructuring, reality testing, and training in emotion regulation strategies. CBTp (CBT for psychosis) techniques developed for the schizophrenia spectrum are also applicable to patients with schizotypy.
Social skills training and supportive treatment: Social skills training to improve social isolation and interpersonal difficulties may be provided in group or individual form. Behavioral therapy techniques such as role play, modeling, and feedback are used, and communication skills, emotion recognition and expression, and assertiveness are practiced. Supportive psychotherapy aims to form a therapeutic alliance with the patient, manage stress, maintain daily living function, and strengthen social connection.
Neurocognitive rehabilitation: When neurocognitive deficits are marked, cognitive remediation therapy (CRT) programs can help improve working memory, processing speed, and executive function. Computer-based cognitive training programs are used as a supplement.
The prognosis of schizotypal disorder varies by individual and is greatly influenced by whether treatment is received, comorbidity, and the degree of social support. Overall the course is often chronic, but the majority maintain some degree of social function without progressing to full schizophrenia.
Transition to schizophrenia: Long-term follow-up studies report that about 10–20% of patients with schizotypal disorder progress to schizophrenia or schizoaffective disorder within 10 years. Risk factors for transition include severity of odd beliefs, degree of neurocognitive deficits, family history of schizophrenia, cannabis use, and low social support. Evidence is accumulating that early intervention in patients assessed as being at high risk of transition (clinical high-risk state) can delay or prevent transition.
Social and occupational functioning: Chronic social isolation and reduced occupational functioning are observed in many patients with schizotypal disorder. However, the ability to live independently and maintain employment is relatively higher than in patients with schizophrenia. Quality of life is negatively affected mainly by social isolation and cognitive deficits. There is evidence that cognitive remediation and social skills training contribute to improved occupational functioning.
Comorbidity and prognosis: Comorbidity with major depressive disorder and social anxiety disorder is associated with overall functional decline and reduced quality of life. Substance use disorder (especially cannabis) is associated with symptom worsening and increased risk of transition to schizophrenia. Actively treating such comorbidities is important for improving overall prognosis.
Factors affecting long-term prognosis: Early diagnosis and treatment initiation, sustained treatment engagement, strength of the social support network, educational level, and level of neurocognitive function are important predictors of long-term prognosis. Family education and a supportive family environment contribute substantially to relapse prevention and maintenance of function.
Prevention of schizotypal disorder focuses mainly on early detection of and intervention in high-risk groups, prevention of symptom worsening, and suppression of transition to schizophrenia. Complete primary prevention (preventing onset itself) is currently not possible, but secondary prevention through risk factor management and early intervention is clinically important.
Early detection and monitoring of high-risk groups: First-degree relatives of patients with schizophrenia have a risk of schizotypal disorder 3–5 times that of the general population, so regular mental health assessment is recommended. When prodromal symptoms such as social withdrawal, decline in academic functioning, and odd thinking appear in adolescents and young adults, referral to an early psychosis clinic or mental health welfare center is needed. Systematic assessment and monitoring through clinical high-risk (CHR) programs form the basis of early intervention.
Substance use prevention: Cannabis use is a strong environmental risk factor that induces or worsens schizotypal symptoms in individuals with genetic vulnerability and raises the risk of transition to schizophrenia. Education on preventing cannabis and other psychostimulant use for high-risk adolescents is important. Early intervention for other substance use disorders such as alcohol is also needed in parallel.
Stress management and strengthening resilience: Chronic stress, especially social exclusion or traumatic experiences, can trigger symptom onset in individuals with genetic vulnerability. Mindfulness-based stress reduction (MBSR), cognitive behavioral stress management techniques, and increased physical activity help strengthen resilience in vulnerable individuals.
Family education and support: Psychoeducation for the families of patients with schizotypal disorder contributes to understanding the nature of the illness, acquiring appropriate communication styles, and creating a supportive environment for the patient. Reduced expressed emotion (EE) within the family is associated with lower relapse rates. Family-based intervention programs are effective in improving the quality of life of both patients and families.
Raine A. Schizotypal personality: neurodevelopmental and psychosocial trajectories. Annual Review of Clinical Psychology. 2006;2:291-326. DOI: 10.1146/annurev.clinpsy.2.022305.095318. PMID: 17716073.
Fonseca-Pedrero E, Debbané M. Schizotypal traits and psychosis risk: An updated systematic review. Psychopathology. 2017;50(4):277-290. DOI: 10.1159/000477169. PMID: 28848098.
Meehl PE. Schizotaxia revisited. Archives of General Psychiatry. 1989;46(10):935-944. DOI: 10.1001/archpsyc.1989.01810100077015. PMID: 2552878.
Kety SS, Wender PH, Jacobsen B, et al. Mental illness in the biological and adoptive relatives of schizophrenic adoptees. Archives of General Psychiatry. 1994;51(6):442-455. DOI: 10.1001/archpsyc.1994.03950060006001. PMID: 8192548.
Rosell DR, Futterman SE, McMaster A, Siever LJ. Schizotypal personality disorder: a current review. Current Psychiatry Reports. 2014;16(7):452. DOI: 10.1007/s11920-014-0452-1. PMID: 24828284.
McClure MM, Barch DM, Flory JD, Harvey PD, Siever LJ. Context processing in schizotypal personality disorder: evidence of specificity of impairment to the schizophrenia spectrum. Journal of Abnormal Psychology. 2008;117(2):342-354. DOI: 10.1037/0021-843X.117.2.342. PMID: 18489210.
Nordgaard J, Revsbech R, Sæbye D, Parnas J. Assessing the diagnostic validity of a structured psychiatric interview in a first-admission hospital sample. World Psychiatry. 2012;11(3):181-185. DOI: 10.1002/j.2051-5545.2012.tb00131.x. PMID: 22943837.
Kwapil TR, Barrantes-Vidal N. Schizotypy: looking back and moving forward. Schizophrenia Bulletin. 2015;41(Suppl 2):S366-373. DOI: 10.1093/schbul/sbu186. PMID: 25548385.
Chun J, Kwon JS. Schizotypal features in patients with ultra-high risk for psychosis. Psychiatry Investigation. 2011;8(3):228-235. DOI: 10.4306/pi.2011.8.3.228. PMID: 21994506.
World Health Organization. ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines. Geneva: WHO; 1992. (See classification criteria for F21 schizotypal disorder.)